IntroductionHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from ...

Researchers from the University of Illinois have identified a key process coordinating liver maturation and polyploidization, a state in which cells carry more than two sets of chromosomes. Their ...

A new blood test was found to detect colon cancer with more than 80% accuracy — and to rule it out for 90% of healthy people. The results were presented at the 2025 American Society of Clinical ...

“Currently, lifestyle intervention (diet and exercise) is the only therapeutic recommendation for compensated MASH-related cirrhosis,” senior investigator Dr. Steven Nissen, chief academic officer of ...

What Is an ALT Blood Test? The alanine aminotransferase (ALT) test is a blood test that checks for liver damage. ALT used to be called serum glutamic-pyruvic transaminase (SGPT). Your doctor can ...

The test was 81% accurate in detecting colon cancer among people with the disease It also was 90% accurate in ruling out colon cancer among healthy people TUESDAY, Jan. 28, 2025 (HealthDay News) -- An ...

Taking to TikTok, Dr Zain Hasan said: "Liver cancer is typically detected by accident, not by intention" he said. "[This] means that usually either your blood test come[s] up abnormally high or ...

A second blood test shows promise for the detection of colon cancer, according to a new study. The first, called Shield, was approved by the Food and Drug Administration in July for people 45 and ...

However, there is no national screening programme and men need to request a blood test from their GP when they are over 50. Prostate Cancer Research is calling for the government to ensure the NHS ...

The prognostic value of HER2 gene dosage and heterogeneity at a single-cell resolution in gastroesophageal adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

PFS was based on RECICL (Response Evaluation Criteria in Cancer of the Liver) in the intention-to-treat (ITT) population. The 6-month PFS was 70.8% with TACE-CR and 31.5% with TACE alone.